Melanoma vaccine and methods of making and using same

Details Melanoma vaccine and methods of making and using same Melanoma vaccine and methods of making and using same

2006-03-21

2006-03-21

Wehbe′, Anne M. (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S093200, C424S093100, C435S320100, C435S325000, C435S455000

Reexamination Certificate

active

07015205

ABSTRACT:
An immunotherapeutic vaccine providing antigen presenting cells that have been pulsed with a disrupted cell preparation which includes enucleated cytosol and cell membranes of cancer cells infected with a recombinant vaccinia virus encoding at least one immunostimulating molecule. In a preferred embodiment, the vaccine includes autologous dendritic/monocytic cells (DC/M) that present a mixture of antigens (present in the enucleated cytosol and cell membranes) from melanoma cell lines that have been infected with a recombinant vaccinia virus encoding IL-2. In another of the preferred embodiments, the enucleated cytosol and cell membranes are from melanoma cells harvested from the patient to be treated. A method of making the vaccine and methods of using the vaccine to stimulate an anti-cancer immune response and to treat a patient with a cancer are also described.

REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 4863727 (1989-09-01), Zimmerman et al.
patent: 5030621 (1991-07-01), Bystryn
patent: 5066489 (1991-11-01), Paradise et al.
patent: 5290551 (1994-03-01), Berd
patent: 5425940 (1995-06-01), Zimmerman et al.
patent: 5478556 (1995-12-01), Elliott et al.
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5635188 (1997-06-01), Bystryn
patent: 5788963 (1998-08-01), Murphy et al.
Sivanandham et al. (1994) J. Immunol. Immunother., vol. 38, 259-264.
Nestle et al. (1998) Nat. Med., vol. 4, No. 3, 328-332.
Pardoll (1998) Nat. Med. vol. 4 (5 Suppl), 525-531.
Kaufman (1995) Annu. Rev. Immunol., vol. 13.
Tueting T. et al., “Autologous Human Monocyte-derived Dendritic Cell Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses in Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-biasing Cytokines IL-12 and IFN-α1”, J. Immunol. vol. 160, 1998, pp. 1139-1147.
Quin H. et al., “Recombinant Vaccinia Expressing Interleukin-2 for Cancer Gene Therapy”, Cancer Gene Therapy, vol. 3, No. 3, 1996, pp. 163-167.
Abde-Wahab Z. et al., “Human Dendritic Cells, Pulsed with Either Melanoma Tumor Cell Lysates or the Gp100 Peptide (280-288), Induce Pairs of T-cell Cultures with Similar Phenotype and Lytic Activity”, Cellular Immunology, vol. 186, No. 1, May 25, 1998 (pp. 63-74).
Sivanandham M. et al., “Prospects for Gene Therapy and Lymphokine Therapy for Metastatic Malanoma”, Ann. Plastic Surg., vol. 28, No. 1, 1992, pp. 114-118.
Mukherji B and Chakraborty NG., “Immunobiology and immunotherapy of melanoma,” Curr.Opin.Oncol.7:175-184, 1995.
Wallack MK, Sivanandham M, Balch CM, et al., “Favorable Clinical Responses In Subsets of Patients From A Randomized, Multi-Institutional Melanoma Vaccine Trial,” Ann.Surg.Oncol.3(2):1-8, 1996.
Lotze MT et al., “High dose recombinant interleukin-2 in the treatment of patients with disseminated cancers,” JAMA 256(22):3117-3124, 1986.
West WH et al., “Constant infusion of recombinant IL-2 in adoptive immunotherapy of advanced cancers,” New Engl.J.Med. 316(15):898-905, 1987.
Qin H, Catterjee SK, “Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF,” Hum. Gene Ther. 7(15):1853-60, Oct. 1, 1996.
Shrayer DP, Bogaars H, Hearing VJ, Wanebo HJ, “Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy,” J.Exp.Ther.Oncol., 1(2):126-33, 1996.
Rosenberg et al., “Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma,” New Engl.J.Med.319:1676-1680, 1988.
Dutcher et al., “A Phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma,” J.Clin.Oncol. 9(4):641-648, 1991.
Siegel et al., “Interleukin-2 toxicity,” J.Clin.Oncology, 9:694-704, 1991.
Pardoll DM,“Cancer vaccines,” Nat.Med. 4(5 Suppl): 525-31, 1998.
Nestle FO et al., “Vaccination of melanoma patients with peptide- or tumor lysate pulsed dendritic cells,” Nat.Med.4(3):328-332, 1998.
Hsu et al., “Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells,” Nat.Med. 2(1):52-58, 1996.
Villikka K et al, “Cytokine therapy of maglignant melanoma,” Ann.Med.28(3):227-233, 1996.
Kirkin AF et al., “Generation of human-melanoma-specific T lymphocyte, clones defining novel cytolytic targets with panels of newly established melanoma cell lines,” Cancer Immunol. Immunother.41(2):71-81, 1995.
Celluzzi CM et al., “Cutting Edge: Physical interaction bewteen dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection,” J.Immunol.160(7):3081-3085, 1998.
Flexner C et al., “Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression,” Nature 330:259-262, 1987.
Sivanandham M et al., “Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model,” Cancer Immunol. Immunother.38:259-264, 1994.
Lee SS et al., Vaccinia virus vector mediated cytokine gene transfer for in vivo tumor immunotherapy, Proc.Am.Assoc.Can.Res.1035:514, 1994.
Miyahira Y et al., “Quantification of antigen specific CD8+ T cells using an ELISPOT assay”, J. Immunol.Meth.181:45-54, 1995.

Affiliated with

Also associated with

Rating

Melanoma vaccine and methods of making and using same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Melanoma vaccine and methods of making and using same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanoma vaccine and methods of making and using same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3609027